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Abstract: Enteroviruses (EVs) have long been implicated in the pathogenesis of type 1 diabetes (T1D),
and accumulating evidence has associated virus-induced autoimmunity with the loss of pancreatic
beta cells in T1D. Inflammatory cytokines including interferons (IFN) form a primary line of defence
against viral infections, and their chronic elevation is a hallmark feature of many autoimmune
diseases. IFNs play a key role in activating and regulating innate and adaptive immune responses,
and to do so they modulate the expression of networks of genes and transcription factors known
generically as IFN stimulated genes (ISGs). ISGs in turn modulate critical cellular processes ranging
from cellular metabolism and growth regulation to endoplasmic reticulum (ER) stress and apoptosis.
More recent studies have revealed that IFNs also modulate gene expression at an epigenetic as well
as post-transcriptional and post-translational levels. As such, IFNs form a key link connecting the
various genetic, environmental and immunological factors involved in the initiation and progression
of T1D. Therefore, gaining an improved understanding of the mechanisms by which IFNs modulate
beta cell function and survival is crucial in explaining the pathogenesis of virally-induced T1D.
This should provide the means to prevent, decelerate or even reverse beta cell impairment.
Keywords: enterovirus; Interferon Stimulated Genes (ISG); Endoplasmic Reticulum (ER) stress;
apoptosis; innate immunity; autoimmune disease
1. Introduction
Type 1 diabetes (T1D) is a chronic autoimmune disease characterised by reduced insulin production
and caused by a specific immune-mediated loss of insulin producing beta cells [1,2]. Aetiologically,
the initiation and progression of T1D occurs as a consequence of a complex interplay between genetic,
immunological and environmental factors. A number of genes and their variants have been linked to
risk of T1D, the majority of which are associated with immune responses or modulation of immune
pathways [3]. From an environmental perspective, factors such as diet, gut microbiota and infections
have been indicated as triggers of T1D [2]. Among the infectious agents, many studies have implicated
infection by enteroviruses (EVs), but it has not been established which EV serotypes (among the more
than 100 known) are involved. The available evidence supports infection by various strains of the
Coxsackievirus B (CVB) and some Echoviruses [4–21], but various other viruses including rubella,
mumps, reoviruses, parvoviruses and cytomegalovirus have also been linked to T1D [22,23]. However,
evidence for the implication of the latter viruses in T1D has been challenged on the basis of a weak
link and/or irreproducibility of the association [24]. In addition, it has been noted that despite the
eradication of mumps and rubella viruses following large-scale vaccination programmes in many
countries, the incidence of autoimmune diseases such as T1D has risen, arguing against this and
suggesting that their lack, rather than their presence, may have contributed to increasing incidence of
T1D [25]. Nevertheless, EVs are the most commonly identified (and studied) viruses in epidemiological,
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clinical and histopathology studies of T1D [26]. EVs display a tropism for beta cells and expression of
the Coxsackie and adenovirus receptor (CAR, CXADR), one of the key entry receptors for the CVB
strains, has been demonstrated in beta cells [27,28], suggesting that systemic infections might culminate
in the entry of EVs into these cells. In support of this, both enteroviral RNA and the viral capsid
protein 1 (VP1), have been detected at low levels, in the pancreas of people with type 1 diabetes at a
higher frequency than in control subjects [29]. Such evidence has been interpreted as evidence of the
persistence of a low grade infection in beta cells [7,30]. A temporal association between EV infection
and seroconversion to islet cell antibody (ICA) immunopositivity has also been described [31], and a
meta-analysis of twenty six case control studies concluded that EV infection is significantly linked with
autoimmunity and T1D [20]. EV RNA has also been detected in peripheral blood mononuclear cells
(PBMC) of recent onset T1D patients at a higher frequency than in nondiabetic control subjects [29,32],
and the presence of EV RNA in the serum of patients has been suggested as a risk factor for beta cell
autoimmunity and T1D [33].
The development of T1D has been associated with infection by particular CVB serotypes,
since, for instance, an increased incidence of T1D was reported following epidemics of CVB4 and
CVB5 [34,35], whilst an antibody survey of different European populations suggested that seropositivity
for anti-CVB1 antibodies is associated with beta cell autoimmunity and increased risk of T1D [36,37].
The chronological order of infection with different CVB serotypes may also influence the outcome
of the immune response. For example, infection with CVB3 or CVB6 prior to infection with CVB1
may reduce the risk of developing autoantibodies compared to when CVB1 infection occurs first [36].
A more recent large scale study of virome in the stools of children from four countries has shown
that prolonged shedding of EV-B is associated with an increased likelihood that islet autoimmunity
will develop [38]. Nevertheless, despite the accumulation of a significant volume of evidence over
a prolonged period, the demonstration of a causal link between the EV infection of islet cells and
the onset of T1D is still to be fully verified [39], and it will require the development of a successful
vaccination strategy before the issue is finally resolved.
While numerous clinical, epidemiological and experimental studies have associated viruses with
T1D, few studies have investigated the efficacy and immunogenicity of vaccines in relation to T1D.
Recent evidence has implicated rotavirus vaccination as a means to reduce the incidence of T1D [40],
but the weight of the evidence is still debated [41]. Other studies in mouse models of T1D have
shown that mice vaccinated against CVB1 have significantly lower levels of replicating virus both
in their blood and in the pancreas and are protected against T1D acceleration when challenged with
CVB1 [42,43]. An inactivated hexavalent CVB vaccine induces robust antibody responses against the
six known CVB serotypes and has proved safe when administered to mice and nonhuman primates.
Importantly, this vaccine prevented T1D in a mouse model highly susceptible to CVB-induced beta cell
destruction [44].
It may be argued that a causal link between virus infections and autoimmune T1D should imply
a concordant incidence rate between the two. Whilst many studies have implicated virus infections
as promoters of T1D (see above), a few other studies are suggestive of an overall protective role
for viruses against T1D. For instance, lower prevalence of T1D (and other autoimmune diseases) in
equatorial countries compared to northern Europe and north America has been attributed to higher
hygiene standards (and consequently lower infection rates) in the latter regions [45]. This notion
has been supported by epidemiological studies in migrant communities with an increased incidence
rate of T1D in their new country of residence [46–48]. The incidence rate of T1D was also varied
and inversely correlated with frequency of EV antibodies in several northern and eastern European
countries [49,50] even when populations with a similar genetic background, but with different EV
infection rates, were compared [51]. Nevertheless, whilst large scale epidemiological studies to prove
or disprove this notion are still lacking, it is important to emphasise that viruses, even if causally
linked to T1D, are not the sole determinants of beta cell fate. Rather, they are likely to contribute to the
onset and/or progression of autoimmune T1D in the presence of other factors such as a predisposing
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genetic background (which is frequently enriched in specific geographical populations) and an aberrant
immune response against pancreatic beta cells.
Despite these ongoing uncertainties, it is well documented that mammalian cells initiate a
coordinated early phase autonomous response to viral and bacterial infections, which is mediated
by interferons (IFN), especially type I and type III IFNs, and other pro-inflammatory cytokines.
This is manifest in various ways, including by the induction of a plethora of IFN stimulated genes
(ISGs) [52,53]. IFNs typically impact pancreatic beta cell function and survival by augmenting their
intracellular antiviral response mechanisms to mitigate the potentially negative impacts of viral
infection. One such example is suppression of CVB3 infection in pancreatic islets pretreated with
type I and type III IFNs [54]. However, they can also (perhaps inadvertently) increase the visibility of
beta cells to the immune system by, for example, promoting the hyperexpression of human leukocyte
antigen class I (HLA-I) molecules, thereby facilitating the presentation of autoantigens to influent
immune cells. Consistent with this, histopathological examination of pancreas sections has revealed
key inflammatory signatures in the islets of individuals with recent onset T1D. These include an almost
universal hyperexpression of HLA-I molecules and the frequent presence of infiltrating cytotoxic
CD8+ T lymphocytes, CD4+ T cells, CD20+ B cells and macrophages [55,56]. Viral infections are
potent inducers of IFN production, and these appear to play a key role in driving islet inflammation,
as well as being potential mediators of apoptosis and beta cell dysfunction. Supportive evidence for the
importance of the IFN pathway in the development of T1D further derives from studies demonstrating
that aberrant IFN responses triggered either by genetic mutations in key pathways [57] or the activation
of components upstream of IFNs [58] are also associated with disease. Collectively, these findings
imply that the IFN pathway is important for the development of T1D, regardless of whether the initial
trigger is a viral infection, a genetic mutation or the activation of the IFN pathway by other means.
In this review, we provide an overview of recent findings which illuminate the actions of IFNs on beta
cells to show how these cytokines impact and modulate cellular responses in a bid to regulate cell
survival during viral infection.
2. IFNs as a Key Link between Environmental and Genetic Risk Factors of Autoimmune T1D
As a means to develop antiviral defence mechanisms, mammalian cells have evolved several
pattern recognition receptors (PRRs) to sense pathogen associated molecular patterns (PAMP) such
as virally encoded nucleic acids [59]. EVs have a small positive sense single-stranded RNA (ssRNA)
genome which is copied to generate a double-stranded RNA (dsRNA) intermediate during replication
and in chronic stages of infection [60–62]. PRRs form part of an upstream ‘early warning’ system which,
upon activation, induces IFN secretion to signal the presence of viruses to surrounding cells (Figure 1).
Such PRRs include Toll-like receptor 3 (TLR3), melanoma differentiation associated gene 5 (MDA5) and
retinoic acid inducible gene I (RIG-I) [59,63]. TLR3 typically resides in the endosomal compartment
and is predominantly restricted to immune cells [64]. Consistent with this (and noting that the evidence
remains equivocal [65]), we have not been able to detect TLR3 by immunohistochemistry in human
beta cells [5]. By contrast, MDA5 and RIG-I both sense dsRNA species present in the cytoplasm of most
cells [64]. However, activation of RIG-I is restricted to specific triphosphorylated RNA species having
uncapped 5′ termini—a molecular feature normally found in negative sense RNA viruses such as
influenza virus [66]—but it is not activated by EV RNAs which lack a 5′ triphosphate [67]. Importantly,
activation of MDA5 requires a high molecular weight complex RNA structure composed of both ssRNA
and dsRNA [67], and these can be generated during EV infection. Upon engagement with a relevant
ligand, MDA5 monomers form an oligomeric filament along the length of the target RNA and an
assembly of multiple MDA5 N-terminal caspase recruitment domains (CARDs) then recruit interferon
promoter stimulator 1 (IPS-1, also known as MAVS, mitochondrial antiviral signalling protein) [68].
IPS-1 signalling, in turn, engages members of the tumour necrosis factor (TNF) receptor-associated
factor (TRAF) family (e.g., TRAF3 and TRAF6) and TRAF family member-associated nuclear factor
κB (NF-κB) activator (TANK), leading to increased phosphorylation of NF-κB and both interferon
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regulatory factor 3 (IRF3) and IRF7. Upon phosphorylation, these proteins translocate to the nucleus and
induce expression of IFN type I and other potentially pro-inflammatory cytokines such as interleukin
8 (IL-8) and TNFα [69–71]. The IFNs in turn induce expression of a large number of ISGs [52].
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recognition receptors (PRRs) that induce interferons (IFNs) and interferon stimulated genes (ISGs) as
well as PRRs that directly target and cleav viral RNA, driving a c llective intrinsic antiviral response
that may lead to virus clearance or virus persistence. The urge in IFNs and ISGs pro otes Endoplasmic
Reticulum (E ) s ress and unfold d protein response (UPR) which, a one or in combination with
virus infection, may lead to programmed cell death (apoptosis), exposing virus and self-antigens to
the immune ystem. In addition, IFNs promote a tigen presentation and immune cell migrati by
inducing the expression of human leukocyt an igen class I (HLA-I) molecules and ch moki es such
as C-X-C motif chemok ne 10 (CXCL10). Cells with lytic or persiste infection th t do not undergo
apoptosis may present viral antigens (e.g., VP1) and self-antig ns (including neo-antigens ind c d
by IFNs and UPR) to the immune cells (APCs, CD8+ and CD4+ T cells) eading to development of
autoantib dies and an adaptive autoimmune response against antigen producing cells. Islet filtrating
immune c ll may also contribute to ER stress and UPR i beta cells by releasing inflammatory cytokines
such as IFNα and IFNγ. MDA5, m lanom differentiation-associated protein 5; PKR, protein kinase R;
VP1, virus capsid p otein 1.
Type I IFNs have been described as key regulatory links between the innate and adaptive
immune response due to their ability to activate genes that are involved in modulating such
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responses [72]. Of particular relevance to T1D is HLA-I, whose hyperexpression is a frequent
observation in insulin-containing pancreatic islets of people with recent onset T1D [6,56,73]. HLA-I is
an important ISG which has a central role in presenting cytosolic antigens to CD8+ T cells and has
been implicated as one of the major determinants of the beta cell fate in autoimmune T1D [56,72].
A number of studies have implicated local IFN production within the islet milieu in driving
autoimmunity and progression towards clinical T1D. Indeed, type I IFN has been detected directly
within the islets of subjects with T1D [6], and a range of downstream ISGs, such as signal
transducer and activator of transcription 1 (STAT1), IRF1, HLA-E and myxoma resistance protein 1
(Mx1, also known as MXA) are also elevated at both the RNA and protein level in T1D islets [74–76].
Furthermore, HLA-DQB1, an allele of HLA-II, is associated with increased risk of T1D [77,78],
and analysis of whole-blood RNA samples from participants in the Finnish Type 1 Diabetes Prediction
and Prevention (DIPP) study revealed that an innate immune signature is present in children carrying
this allele before detection of islet autoimmunity (seroconversion) [79]. This signature remains active
throughout the period to diagnosis of T1D [79]. Importantly, among the upregulated genes identified
in the seroconverted children were genes belonging to the RIG-I signalling pathway as well as the
transcription factors (TFs) IRF5 and IRF7, all of which are involved in antiviral innate immune responses.
Increases in Eosinophil-derived neurotoxin (EDN) have also been seen in children progressing to
clinical T1D [79], which is significant because EDN (also known as ribonuclease A family 2 (RNASE2))
is a ligand for TLR2 and has been shown to enhance dendritic cell (DC) maturation and migration,
to promote helper T type 2 (Th2) immune responses and to propagate antiviral responses against
ssRNA viruses [80]. Interestingly, EDN upregulation has also been reported in other autoimmune
conditions, including systemic lupus erythematosus (SLE) and rheumatoid arthritis [81,82].
These provocative observations made from in vivo studies have received equally powerful support
from in vitro studies in which isolated human islets were infected with CVB. Thus, a recent study
showed that the infection of human islets with CVB3 induces the upregulation of type I and type III
(IFNλ1 and IFNλ2) IFNs as well as a strong IFN signature manifest as increased ISGs such as ISG15,
STAT1, IRF7, Mx1 and CXCL10 and PRRs MDA5, RIG-I and TLR3 [83].
It is also significant that a nonsynonymous SNP rs1990760 (A946T) found in IFIH1, the gene that
encodes MDA5, is associated with T1D [84]. In particular, the TT and TC genotypes encoded by this
SNP are associated with either an increased risk of, or protection from T1D, respectively. Hierarchical
gene clustering of the TT and TC genotypes of SNP rs1990760 may also be associated with lower or
higher relative ISG gene expression, respectively [83]. These data suggest that, whilst EVs can induce
a strong IFN response in human islets, the precise outcome is influenced by variations in the gene
sequence at such polymorphic sites. A study in a human hepatocyte cell line, Huh7, showed that
the presence of the A946T polymorphism in IFIH1 leads to production of a form of MDA5 capable of
inducing a stronger IFNβ response than that seen with the more common variant. Notably, expression
of the A946T variant MDA5 in Ifih1-depleted mouse embryonic fibroblasts (MEFs) resulted in a failure
to mount an effective IFN response against virus infection [85]. Further investigation revealed that the
A946T variant induces a conformational change which abrogates the ATPase activity of MDA5 [85] that
is essential for filament disassembly and interaction with dsRNA [68]. These data strongly support the
notion that this variant of MDA5 may fail to function effectively as a PRR but, paradoxically, it may
still elicit tissue damage by producing a chronic IFN response even in the absence of a virus infection,
as has been noted in SLE [86].
Variants of IFIH1 have also been associated with type I interferonopathies (a group of
monogenic innate immune disorders characterised by type I IFN overproduction) autoimmunity and
autoinflammation [87]. On this basis, it has even been suggested that a localised islet interferonopathy
may precede EV infection in genetically susceptible individuals and that the burden of a viral infection
may then serve to exacerbate this pre-existing inflammatory condition [87]. As such, constitutive
activation of MDA5 might perpetuate a vicious cycle in which IFNs and ISGs are induced inappropriately
and lead ultimately to apoptosis and/or increased immunogenicity.
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Tyrosine kinase 2 (TYK2) is another key regulator of type I and type III IFN signalling, and gene
variants predicted to decrease TYK2 functionality are associated with a reduced risk of T1D and other
autoimmune conditions [88]. One such variant is TYK2 SNP rs2304256 whose AA genotype has been
associated with reduced IFNα-induced STAT1 phosphorylation [89]. Similarly, knockdown of TYK2
significantly reduces phosphorylation of STAT1 and STAT2, IFNα-induced HLA-I expression and poly
I:C-induced apoptosis in EndoC-βH1 cells [89]. Consistent with these findings, a recent study showed
that the inhibition of TYK2 using novel, selective, drugs prevents IFNα+IL-1β-induced apoptosis in
human islets without affecting normal function and survival of CVB-infected beta cells or islets [90].
3. IFNs Induce Endoplasmic Reticulum Stress, Unfolded Protein Response and Apoptosis
In addition to HLA-I hyperexpression, islet cell ER stress (and the associated unfolded protein
response (UPR)) have been described among the features of T1D [91]. For example, Marroqui et al.
showed that IFNα induces HLA-I and markers of ER stress such as Binding Immunoglobulin Protein
(BIP), C/EBP Homologous Protein (CHOP), Activating Transcription Factor 3 (ATF3) and spliced X-box
Binding Protein 1 (XBP1s) in the human beta cell line EndoC-βH1. They also found similar responses
in the islets of people with recent-onset T1D [91,92]. These changes were reversed in EndoC-βH1 cells
following siRNA-mediated knockdown of TYK2, STAT2 or STAT1+STAT2 [91], indicating that TYK2
and STAT2 play an indispensable role in IFNα-induced HLA-I upregulation and ER stress. Similarly,
knockdown of STAT1 significantly reduced IFNγ-induced HLA-I expression. This is consistent with
the known roles of these proteins as upstream factors involved in IFNα and IFNγ signalling.
IFNα can induce phosphorylation and subsequent formation of both STAT1/STAT2 hetero- and
STAT2/STAT2 homodimers, whereby either dimer can, by recruiting IRF9, induce the expression of
downstream genes by binding to IFN-stimulated response elements (ISRE). IFNγ signalling on the other
hand is more restricted since it promotes the binding of phosphorylated STAT1/STAT1 homodimers to
gamma interferon-activated sites (GAS) [93,94]. A compensatory overexpression of STAT2 following
STAT1 knockdown (and vice versa) [91] may explain the redundancy of STAT1 for IFNα-mediated
induction of HLA-I and ER stress markers.
ER stress is frequently characterised by a sustained activation of UPR—a mechanism which
regulates the protein processing capacity of the ER during conditions such as virus infection [95] and
which can culminate in apoptosis [96,97]. Three branches of the UPR have been described, each regulated
by a principal ER transmembrane sensor, including dsRNA activated protein kinase (PKR)-like ER
kinase (PERK), inositol requiring enzyme 1 (IRE1) and ATF6 [96]. The three branches work in parallel
to sustain protein folding capacity, promote mRNA decay and reduce ER protein flux. Following
activation of ATF6 and its subsequent cleavage in the Golgi apparatus, the cytosolic N-terminal region,
ATF6(N) translocates to the nucleus to promote expression of ER resident chaperones, including
BIP and glucose-regulated protein 94 (GRP94). Accumulation of unfolded proteins in the ER also
induces oligomerisation and autophosphorylation of PERK. Activated PERK in turn phosphorylates
eukaryotic Initiation Factor 2 subunit α (eIF2α), thereby inhibiting translation of the majority of cellular
mRNAs. Exceptions are some mRNAs containing short open reading frames (ORFs) in their 5′ UTR:
one such being ATF4. The renewed translation of ATF4 is enhanced under these conditions and this,
in turn, promotes the expression of CHOP and ATF3. Notably, CHOP activation by this mechanism
has been associated with apoptosis of heart and lung cells in mouse models of CVB3-induced acute
myocarditis and pulmonary fibrosis [98,99]. Finally, the accumulation of unfolded proteins in the
ER lumen promotes the activation and oligomerisation of IRE1α, a protein with dual kinase and
endoribonuclease activity, which then targets XBP1 for splicing. The product (XBP1s) is a transcription
factor which regulates various processes including lipid biosynthesis, expression of protein-folding
chaperones and ER-associated protein degradation (ERAD) [100]. The RNase activity of IRE1α is also
implicated in the mitigation of ER stress by enhancing mRNA degradation in a process known as
IRE1α-dependent degradation (RIDD) [100].
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IFNα-induced apoptosis in the B lymphoma cell line Daudi requires c-Jun N-terminal kinase
1 (JNK1) [101], and it may be significant that IFNγ+ IL-1β also induce apoptosis and promote activation
of IRE1α and JNK1 in EndoC-βH1 cells [92,102]. In addition, either IRE1α knockdown or the use
of tauroursodeoxycholic acid (TUDCA), to attenuate ER stress, decreased JNK phosphorylation and
cytokine-induced apoptosis in EndoC-βH1 cells [92]. Intriguingly, deletion of the ire1α gene results in
a significant reduction in proinsulin synthesis, insulin content and insulin secretion without affecting
preproinsulin mRNA levels in mouse beta cells. This correlated with increases in the ER stress markers
CHOP, BIP and GRP94 [100]. IFNα-induced ER stress has also been shown to cause an increase in
proinsulin to insulin ratio and to reduce beta cell insulin content as well as the expression of proinsulin
convertase 1/3 (PC1/3) and PC2 in EndoC-βH1 and human islets. Pretreatment with TUDCA and
4-phenyl butyric acid (PBA) reversed all the IFNα-induced effects, suggesting that these changes are
mediated by ER stress [103].
Several viruses (including hepatitis C and hepatitis B viruses, Japanese encephalitis virus and
human cytomegalovirus) can activate both UPR and the IRE1α/XBP1 pathway to facilitate their
own replication [104]. In addition, a recent study revealed that CVB5 infection triggers the PERK
and IRE1α branches of UPR in EndoC-βH1 and in the rat beta cell line, INS-1E [105]. Following
CVB5 infection, a fully activated IRE1α/XBP1s pathway promoted phosphorylation and activation
of JNK1, leading to an increase in viral replication and, ultimately, apoptosis. Conversely, siRNA
mediated IRE1α knockdown or chemical inhibition of JNK1 reduced both responses [105]. Importantly,
the pro-apoptotic and virus-activating effects of JNK1 were regulated independently. These findings
suggest that IRE1α-induced JNK1 activation may be required for efficient CVB replication in pancreatic
beta cells. The same study also showed that despite activation of the PERK pathway in virally infected
cells, none of the downstream ER stress markers—CHOP, ATF4 and ATF3—were induced, suggesting
an incomplete activation of this branch of the UPR [105]. Enteroviruses depend on internal ribosome
entry sites (IRES) to mediate protein translation and replication, and it has been shown that eIF2α is
also required for IRES-dependent translation initiation [106]. These findings suggest that some EVs
have evolved to take advantage of the selective UPR response occurring in beta cells during infection,
but how they achieve this and what role IFNs play are still an open question.
4. IFNs May Promote the Expression of Neo-Antigens in Beta Cells
A recent study shed new light on the processes by which beta cell autoantigens may be generated
during the progression to T1D and hinted that this process is exacerbated during islet inflammation and
viral infection. In particular, it was noted that synthesis of insulin DRiPs (defective ribosomal products)
may be increased under stress conditions [107]. Insulin DRiPs are proteins which arise from aberrant
translation of the insulin mRNA by initiation at one or more AUG codons located downstream (3′) of
the usual initiation site and which are out of frame with the insulin protein. Accordingly, the resultant
protein has a unique sequence which bears no relation to the primary structure of insulin and which may,
as a result, have heightened antigenicity. The authors demonstrated that the newly generated epitopes
have a strong binding affinity for HLA-A2 and that CD8+ T cells directed against a DRiP epitope
are present at significantly higher frequencies in the peripheral blood of people with T1D vs. healthy
donors. Moreover, activated peptide-specific cytotoxic T cells (CTLs) can specifically kill beta cells
obtained from HLA-A2+ T1D donors. Intriguingly, when islets were exposed to a combination of high
glucose, IFNγ and IL-1β, the killing of beta cells was enhanced by activated INS-DRiP1-9-specific CTL,
suggesting that inflammatory cytokines and ER stress may enhance production of INS-DRiP and T cell
mediated beta cell killing [107].
Protein deamidation is a post-translational modification (PTM) which has been suggested as an
underlying immunogenic mechanism for the generation of novel islet autoantigens in individuals
with high risk HLA-DQ2/DQ8 [108]. Tissue transglutaminase (tTG) has deamidase activity and is
expressed in human islets and DCs. Importantly, exposure to IFNγ + IL-1β enhanced tTG activity
in islets and tolerogenic DC (tolDC). In addition, supernatants from activated GAD65-specific CD4+
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T cells had elevated levels of inflammatory cytokines, including IFNγ, IL-1β and TNFα and exposure
of islets to these supernatants promoted deamidation of two glutamine residues in the C-peptide
region of proinsulin, whereas islets incubated with supernatants from resting CD4+ T cells produced
only native C-peptide [108]. Furthermore, DCs from people heterozygous for HLA-DQ2/DQ8, but not
those who are homozygous for HLA-DQ2 or HLA-DQ8, produced deamidated Islet Antigen 2 (IA-2)
molecules when pulsed with native IA-2. Intriguingly, in comparison with native IA-2, the deamidated
variants bind to DQ8trans and/or DQ8cis molecules with higher affinity than the native protein in
cell-free assays [108]. To date, a number of T1D associated neo-antigens and the underlying PTM
have been described [109–116]. These findings suggest that islet inflammation can potentially promote
the formation of neo-antigens by post-translational modification of islet proteins, thereby creating an
immunogenic milieu conducive to the development of autoimmunity.
5. Epigenetic Modulation of Cellular Responses by IFNs
Inflammatory cytokines can also modulate cellular responses at the epigenetic level. Changes in
DNA methylation (DNAm) have been reported in whole blood and monocytes of T1D patients [117,118],
and IFNs can significantly alter chromatin accessibility and DNAm patterns in islet cells [53,75,119].
A multi-omics analysis of human beta cells revealed extensive changes in chromatin accessibility
associated with altered mRNA and protein expression following exposure to IFNα [75]. Intriguingly,
whilst IFNα caused a marked increase in the proportion of accessible chromatin as early as 2 h
after stimulation, these effects were significantly reduced after 24 h of IFNα exposure, indicative
of a dual regulation involving ‘early’ and ‘late’ response regions [75]. The newly accessible open
chromatin regions (OCRs) were enriched for TF binding motifs and mapped predominantly to regions
downstream of transcription start sites (TSS). Importantly, the comparison of RNA-seq data revealed a
significant overlap between the gene expression profiles seen in IFNα-treated islets (and beta cells)
and those obtained from islets of people with T1D [120]. A similar correlation was not seen when islets
from people with T2D were examined [75,121].
Epigenetic DNA hypomethylation is a feature of IFNα-treated islets, and the changes occur most
often in pathways associated with the regulation of apoptosis, protein phosphorylation and fatty
acid oxidation [53]. In addition, such alterations are over-represented in immune-related pathways,
including those involved in antigen processing and presentation, and host defence responses to virus.
Ingenuity Pathway Analysis (IPA) has pointed to STATs and IRFs as primary regulators of IFNα-induced
transcripts, with IRF7 playing a dominant role. DNA demethylation is generally considered to facilitate
gene transcription and integration of data relating methylation changes with mRNA upregulation
during IFNα treatment identifies biological processes such as host defence responses to viral infection
and innate immune responses [53]. The enzyme Ten-eleven translocation (TET) methylcytosine
dioxygenase 2 (TET2) catalyses DNA demethylation by converting 5-methylcytosine (5mC) to
5-hydroxymethylcytosine (5hmC) and is activated in cells exposed to IFNα [53]. This correlates
with an increase in the activity of polynucleotide phosphorylase (PNPase) also known as PNPT1,
an exoribonuclease which degrades a specific miRNA, miR-26a, involved in the negative regulation
of TET2 [53]. Hence, by inducing miR-26a degradation, IFNα indirectly promotes TET2-mediated
DNA demethylation.
In addition to IFNα, other pro-inflammatory cytokines also induce changes in DNA methylation,
histone modification and chromatin remodelling. Thus, newly accessible chromatin regions have also
been identified in human islets and EndoC-βH1 cells exposed to IFNγ + IL-1β. In common with
the OCRs induced by IFNα, induced regulatory elements (IREs) are characterised by the presence of
abundant TF binding sites and are often localised distal to TSS. Further analysis identified two distinct
IREs that become co-occupied and activated by inflammatory TFs upon cytokine exposure. Notably,
these sites are enriched in polymorphic T1D risk variants [119].
Processes leading to miRNA dysregulation occur in cells during either acute or persistent infection
with CVB. For example, 33 miRNAs were altered in expression by at least 3-fold when human islets
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were infected with CVB5 [122]. Similarly, in the pancreatic ductal cell line PANC-1, 81 miRNAs were
altered during persistent infection with CVB4 [123]. In silico miRNA target scanning identified 57 and
49 candidate T1D risk genes as putative targets of the differentially expressed miRNAs in CVB5-infected
islets and CVB4-infected PANC-1, respectively. Whilst these findings support the notion that miRNAs
contribute to the altered cellular milieu during EV infection [124], both studies limited their search
to target transcripts in T1D risk genes. Using a different approach, the expression of 57 miRNAs
was altered by at least 2-fold in IFNγ + IL-1β-stimulated human islets [125]. Among these were
miR-23b-3p and miR-149-5p which were also either down- (miR-23b-3p) or up-regulated (miR-149-5p)
in CVB4-infected PANC-1 cells [123]. These changes led to alterations in various members of the Bcl-2
(B cell lymphoma 2) family, critical regulators of apoptosis, including P53 Up-regulated Modulator
of Apoptosis (PUMA), Death Protein 5 (DP5), PMA-Induced Protein 1 (also known as NOXA),
Bcl2 Associated X Protein (BAX) and Bcl-2-Like Protein 11 (also known as BIM) [125]. Thus, altered
miRNA expression may be an important mechanism by which cells respond to IFNs and modulate
sensitivity to apoptosis.
Finally, in addition to epigenetic processes, other aspects of islet cell gene expression are also
modulated by IFNα. For example, exposure of EndoC-βH1 cells or human islets to IFNα influences
the cellular splicing machinery leading to modified TSS usage and intron removal and generation of
alternatively spliced proteins. This is important because such modifications may lead to intron retention
which has often been associated with alterations in mRNA stability and translation efficiency [126].
Such modulatory effects of IFNα are in line with its antiviral role, since these effects are usually
associated with the selective regulation of protein isoforms having either antiviral functions or roles in
virus replication [75,127].
6. IFN-Mediated Antiviral Responses May Determine the Fate of Infected Cells
It has been suggested that defective immune responses against CVB infection could be linked to
the loss of immune tolerance to insulin in children in their first years of life [128]. This is important
because both type I and type III IFNs play a role in driving the host response to CVBs in human
islets [83]. However, in order to offset this response, it has also been suggested that CVB3 may block
production of type I and type III IFNs by islet cells [129]. Thus, Lind et al. noted that whereas treatment
with the viral dsRNA mimetic, poly I:C, significantly increased the production of IFNλ1, IFNλ2 and
IFNβ in HeLa cells, their expression remained unchanged after acute CVB3 infection [129].
Studies in individuals with Idiopathic Dilated Cardiomyopathy (IDCM) have revealed the
development of 5′ terminal deletions (5′-TD) in the CVB3 RNA genome during viral persistence
in cardiomyocytes [60]. This unexpected genome modification may then underlie the ability of the
virus to persist in the cells over long periods. Consistent with this notion, detailed mechanistic
studies imply that whereas 5′-TD CVB3 has an attenuated replication efficiency, these viruses can still
maintain a low grade infection and support functionally competent processes that allow disruption
of the host cell protein translation machinery [60]. It is not known whether 5′-TD accounts for the
persistence of EVs following infection of human beta cells (although this has been proposed in mouse
pancreas [130]), but the concept that persistent infection can be sustained in these cells is concordant
with evidence of VP1 detection in a small number of beta cells of individuals with both recent
onset and longer duration T1D [4,7,131]. In this scenario, it is proposed that an attenuated antiviral
response may facilitate virus persistence, thereby allowing the host and virus to co-exist without the
development of large-scale beta cell lysis. Studies of subjects with fulminant type 1 diabetes (which is
also associated with EV infection) imply that the consequences of a full-blown lytic EV infection are
catastrophic at the level of the endocrine pancreas [132]. It is, therefore, plausible that, in cases of T1D
associated with sublytic EV infections, there is early production of type I and type III IFNs leading to
upregulation of cellular ribonucleases (such as IFN-induced protein with tetratricopeptide repeats
1 (IFIT1), ribonuclease L (RNase L), 2′-5′-oligoadenylate synthetase 1 (OAS1), adenosine deaminase
Microorganisms 2020, 8, 1419 10 of 18
acting on RNA 1 (ADAR1) and PKR) [59] and that these promote the formation of 5′ deletions within
the viral RNA to facilitate persistence.
7. IFNs as Regulators of Cell Mediated Immunity
It might be envisaged that continuous application of IFN-induced cellular stress would ultimately
promote beta cell death and the generation of neo-antigens. Such neo-antigens might then be
endocytosed and presented by plasmacytoid DCs (pDCs) to mediate the activation and maturation
of autoreactive CD8+ T and CD4+ T cells [133]. Autoreactive CD8+ T and CD4+ T cells can in turn
target the source of these autoantigens for specific killing (Figure 1). Activation, proliferation and
differentiation of CD8+ T cells depends on the availability of three key factors including HLA-I-mediated
antigen presentation, the presence of costimulatory signals and inflammatory cytokines [134,135].
Type I IFNs have been highlighted as important in this context [134].
PDCs are an important source of type I IFN, and their numbers are increased in individuals at risk
of T1D as well as in those with recent onset and established T1D [136]. PDCs from people with T1D
express higher levels of HLA-DR compared to those from healthy control subjects, and they produce
IFNα when stimulated with CVB4. Exposure of CD4+ and CD8+ T cells from healthy donors to
IFNα-producing pDCs enhanced the production of IFNγ, but this was even more evident in subjects
with T1D [136]. These findings support a role for pDCs as a potential source of type I IFNs in T1D.
A role for pDCs in the initiation of autoimmune diabetes has also been highlighted by observations
that pDC depletion significantly delays the onset in non-obese diabetic (NOD) mice [137]. Importantly,
a recent study has shown expression of HLA-II on a subset of pancreatic beta cells from donors with
recent onset T1D [120]. Since HLA-II is normally only expressed by professional antigen presenting
cells (APCs) such as DCs, it has been suggested that HLA-II-expressing beta cells may substitute
for DCs by directly presenting islet autoantigens to CD4+ T cells [120]. It remains to be established
whether the small subpopulation of HLA-II expressing beta cells is an important source of type I and
type III IFNs, but this warrants consideration.
Programmed cell death protein 1 (PD-1) and its ligand PDL-1 play a key role in regulating
the proliferation of Ag-specific CD8+ T cells, and they have become the focus of effective therapies
targeting several malignancies [138]. In this context, it is noteworthy that increasing numbers of
cases are being reported in which an unexpected outcome of such therapeutic strategies is the acute
onset of a syndrome with the features of T1D [139]. This suggests that interference in PDL-1/PD-1
signalling may be detrimental to beta cell survival under certain circumstances. Consistent with this,
we found that beta cell PDL-1 expression is induced in parallel with islet inflammation in human
subjects with recent-onset T1D [76]. Thus, it seems possible that islets respond to inflammatory attack
by upregulation of PDL-1 as a defensive mechanism to impede the actions of influent immune cells.
Similarly, they also increase the expression of HLA-E under these conditions. HLA-E is a non-classical
member of the HLA class I family, which also plays a role in islet protection by interaction with
innate immune cells, such as NK cells, which may also be present in the infiltrates [75]. Importantly,
both PDL-1 and HLA-E are induced by exposure of human islets to IFNα, and this may be secondary
to induction of the transcription factor IRF1 [75,140].
Finally, in this context, we note that infection of pancreatic islets with CVB1-7 or stimulation
of EndoC-βH1 cells with IL-1β + IFNγ promotes IL-32 expression [141]. IL-32 isoforms have been
implicated in DC maturation and DC-induced chemotaxis of activated CD4+ and CD8+ T cells [142].
Interestingly, in HLA-DR-DQ conferred children who developed islet autoantibodies or T1D, elevated
expression of IL-32 has been found in CD4+ and CD8+ T cells and NK cells [141].
8. Conclusions
Taken together, the studies summarised in this review imply that virally-induced production of
type I and type III IFNs may be a critical factor that underpins the development of autoimmunity
in genetically susceptible individuals who are progressing to type 1 diabetes. Interventions that
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minimise viral infection may, therefore, prove to be an effective means to slow the rate of progression
in such individuals. As such, we await, with great interest and optimism, the outcome of clinical trials
employing either antiviral agents or an anti-EV vaccine in relevant subjects.
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